Clinical trials
Non Small Cell Lung Cancer clinical trials
Below are recruiting non small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT05242965RecruitingPhase 2
STEMVAC vaccine with pembrolizumab for advanced lung cancer
This trial tests a cancer vaccine called STEMVAC for people with advanced non-small cell lung cancer. The vaccine is given along with ongoing maintenance immunotherapy (pembrolizumab) to see if it can help keep the cancer from growing.
Omaha, NebraskaAges 18 years+ - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Scottsdale, ArizonaAges 18 years+ - NCT05234307RecruitingPhase 1
Nivolumab plus PBF-1129 for advanced lung cancer
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
Columbus, OhioAges 18 years+ - NCT05254184RecruitingPhase 1
Vaccine and immunotherapy for KRAS-mutated lung cancer
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Baltimore, MarylandAges 18–100 - NCT05254782Recruiting
Blood test after lung tumor surgery to find hidden disease
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Toronto, OntarioAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Glendale, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT05167487Recruiting
Study of treatment effects after chemotherapy and surgery for lung cancer
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
A Coruña, A CoruñaAges 18 years+ - NCT05145244Recruiting
Copenhagen observational study for lung or breast cancer data
This is an observational study that collects real-world information from adults with lung cancer or breast cancer. It may help doctors better understand how people do over time and how treatments and outcomes relate to details from your medical record and tests.
CopenhagenAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05102110Recruiting
Check rectal mucus in people with throat or lung cancers
This study looks at a substance called rectal mucus during an exam to learn about changes in people with cancers of the throat/airways (aero-digestive tract). It’s a feasibility study, meaning it mainly tests whether this approach is safe and practical.
ExeterAges 18–99 - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Tucson, ArizonaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05100069Recruiting
Survey about brigatinib for ALK-positive lung cancer
This trial is a survey study about how brigatinib is used for people with certain advanced lung cancer. It may help doctors understand real-world treatment patterns and experiences for ALK-positive non-small cell lung cancer.
TokyoAges Any age - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Gilbert, ArizonaAges 18 years+ - NCT05068232RecruitingPhase 2
Durvalumab plus targeted radiation for metastatic small cell lung cancer
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
Chicago, IllinoisAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05122806Recruiting
Study of cancer biology in ALK-positive advanced lung cancer
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
Saint-Denis, La RéunionAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non small cell lung cancer?
- Yes. Clin2 currently lists 1,366 recruiting non small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Lung Cancer, Non-Small Cell
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.